| Initiated | Sector Perform | X | ||
| Initiated | Overweight | X | ||
| Initiated | Overweight | X | ||
| Initiated | Sector Outperform | X | ||
| Resumed | Buy | X | ||
| Upgrades | Hold Buy | X | ||
| Initiated | Buy | X | ||
| Initiated | Outperform | X | ||
| Initiated | Outperform | X | ||
| Downgrades | Buy Hold | X | ||
| Upgrades | Hold Buy | X | ||
|
$55 $85 |
||||
| Initiated | Neutral | X | ||
| Upgrades | Neutral Buy | X | ||
|
$70 $90 |
||||
| Downgrades | Outperform Neutral | X | ||
|
$50 $70 |
||||
| Downgrades | Outperform Mkt Perform | X | ||
| Downgrades | Buy Hold | X | ||
|
$60 $35 |
||||
| Initiated | Outperform | X | ||
| Initiated | Neutral | X | ||
| Downgrades | Strong Buy Outperform | X | ||
|
$160 $130 |
||||
| Reiterated | Buy | X | ||
|
$155 $145 |
||||
| Reiterated | Buy | X | ||
|
$185 $160 |
||||
| Reiterated | Outperform | X | ||
|
$161 $155 |
||||
| Reiterated | Buy | X | ||
|
$165 $145 |
||||
| Initiated | Strong Buy | X | ||
| Initiated | Buy | X | ||
| Initiated | Equal Weight | X | ||
| Initiated | Buy | X | ||
| Upgrades | Neutral Buy | X | ||
|
$85 $120 |
||||
| Initiated | Buy | X | ||
| Resumed | Hold | X | ||
| Reiterated | Buy | X | ||
|
$62 $65 |
||||
| Upgrades | Neutral Buy | X | ||
| Initiated | Neutral | X | ||
EXAS Exact Sciences Corporation
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
